Boule Diagnostics AB OMXSTO:BOUL:
BOULE DIAGNOSTICS SELECTED AS ONE OF THREE PROVIDERS IN NATIONWIDE HEMATOLOGY TENDER IN ITALY
Boule Diagnostics Selected As Provider In Tender In Italy
Watch Boule Diagnostics' latest callBoule Diagnostics (Stockholm:BOUL) Q3 2026 Earnings Call · Replay · Oct 23Read the transcript of Boule Diagnostics (Stockholm:BOUL) Q3 2026 Earnings CallEarlier from Boule Diagnostics
- Boule Diagnostics CEO Torben Nielsen To Leave Company
- BOUL: Organic growth and strong instrument sales drive improved cash flow amid margin pressure
- Boule Diagnostics CFO Leaves Company
- BOUL: Instrument sales surged 17% but lower prices and costs led to margin decline; cash flow turned positive
- BOUL: Sales fell 25% YoY, but margins improved and OEM growth offset hematology weakness
Later from Boule Diagnostics
- Boule Diagnostics Appoints Michael Af Winklerfelt As CFO
- Boule Diagnostics Renews, Expands Global Supply Agreement
- Boule Diagnostics – Invitation to presentation of the Q4 report 2025
- BOUL: Revenue fell 12% amid restructuring, but operational improvements and portfolio expansion drive future growth
- Boule Diagnostics – Invitation to presentation of the interim report Q1 2026
Follow Boule Diagnostics into a list and get an email when it puts out news.
Follow Boule Diagnostics